Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by kalman007on Nov 24, 2021 1:22pm
168 Views
Post# 34162175

RE:RE:RE:enough is enough

RE:RE:RE:enough is enoughWell I hope you can get out without a loss and preferably we all end up making some back on our investment.  I have a hunch they are not being totally transparent with us; PMN310 goes back to 2018 and as the years go by so does their calendar of bringing it to market which tells me they have no clue what they're doing or the product may not be a slam dunk afterall.  For now, I'll give them the benefit of the doubt that most large pharma companies were too busy making vaccines thereby delaying PMN310.  Maybe Elliot can pop a few pills to smarten up and get this moving.  Furthermore, i don't believe a listing on another exchange is the answer.  If they truly have discovered something, it should be attractive on its own merit, and not need a sexy NYSE listing.  jmo
<< Previous
Bullboard Posts
Next >>